title: On the generation of catalytic antibodies by transition state analogues.
abstract: The effective design of catalytic antibodies represents a major conceptual and practical challenge. It is implicitly assumed that a proper transition state analogue (TSA) can elicit a catalytic antibody (CA) that will catalyze the given reaction in a similar way to an enzyme that would evolve (or was evolved) to catalyze this reaction. However, in most cases it was found that the TSA used produced CAs with relatively low rate enhancement as compared to the corresponding enzymes, when these exist. The present work explores the origin of this problem, by developing two approaches that examine the similarity of the TSA and the corresponding transition state (TS). These analyses are used to assess the proficiency of the CA generated by the given TSA. Both approaches focus on electrostatic effects that have been found to play a major role in enzymatic reactions. The first method uses molecular interaction potentials to look for the similarity between the TSA and the TS and, in principle, to help in designing new haptens by using 3D quantitative structure-activity relationships. The second and more quantitative approach generates a grid of Langevin dipoles, which are polarized by the TSA, and then uses the grid to bind the TS. Comparison of the resulting binding energy with the binding energy of the TS to the grid that was polarized by the TS provides an estimate of the proficiency of the given CA. Our methods are used in examining the origin of the difference between the catalytic power of the 1F7 CA and chorismate mutase. It is demonstrated that the relatively small changes in charge and structure between the TS and TSA are sufficient to account for the difference in proficiency between the CA and the enzyme. Apparently the environment that was preorganized to stabilize the TSA charge distribution does not provide a sufficient stabilization to the TS. The general implications of our findings and the difficulties in designing a perfect TSA are discussed. Finally, the possible use of our approach in screening for an optimal TSA is pointed out.
authors.affiliation: Computational Structural Biology Laboratory, Research Group on Biomedical Informatics (GRIB)-IMIM/UPF Passeig Marítim de la Barceloneta 37-49 08003 Barcelona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Barbany
authors.forename: Hugo
authors.initials: H
authors.lastname: Gutiérrez-de-Terán
authors.forename: Ferran
authors.initials: F
authors.lastname: Sanz
authors.forename: Jordi
authors.initials: J
authors.lastname: Villà-Freixa
authors.forename: Arieh
authors.initials: A
authors.lastname: Warshel
mesh_terms: D017151:Antibodies, Catalytic / Q000737:chemistry*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004355:Drug Stability; D008958:Models, Molecular; D015394:Molecular Structure; D013329:Structure-Activity Relationship
chemical_list: D017151:Antibodies, Catalytic